Wenyan Miao

VP, Immunology at ROME Therapeutics


Wenyan Miao joined ROME after leading drug discovery for autoimmune diseases and immuno-oncology at Celsius Therapeutics as vice president of immunology and inflammation. Prior to that, she served as executive director of immunology at Nimbus Therapeutics. Wenyan also played a major role on the team that led the IND filing and successful Phase I trial of the Nimbus ACC program, which was acquired by Gilead Sciences in 2016 for a total deal value of $1.2 billion. Wenyan has considerable expertise across R&D, from target discovery to early clinical proof-of-mechanism studies. Among her previous positions: posts at Repligen, Pfizer, Wyeth, AbbVie and Millennium Pharmaceuticals. Wenyan has a B.S. in biochemistry from Fudan University in Shanghai and a Ph.D. in biochemistry and molecular biology from Indiana University School of Medicine.


  • VP, Immunology

    Current role

  • VP of Biology & Preclinical Development

View in org chart